Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free CANF Stock Alerts

Can-Fite BioPharma (CANF) Competitors

Can-Fite BioPharma logo
$2.86 -0.05 (-1.75%)
Closing price 03:58 PM Eastern
Extended Trading
$2.81 -0.05 (-1.71%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CANF vs. ADXN, LIMN, SYBX, GNPX, and OBSV

Should you buy Can-Fite BioPharma stock or one of its competitors? MarketBeat compares Can-Fite BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Can-Fite BioPharma include Addex Therapeutics (ADXN), Liminatus Pharma (LIMN), Synlogic (SYBX), Genprex (GNPX), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry.

How does Can-Fite BioPharma compare to Addex Therapeutics?

Can-Fite BioPharma (NYSE:CANF) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Can-Fite BioPharma presently has a consensus price target of $42.50, indicating a potential upside of 1,386.53%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Can-Fite BioPharma's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Addex Therapeutics N/A -105.98%-87.61%

Can-Fite BioPharma has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K4.62-$7.63M-$35.80N/A
Addex Therapeutics$210K39.77-$8.12M-$5.74N/A

Can-Fite BioPharma has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

In the previous week, Addex Therapeutics had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 3 mentions for Addex Therapeutics and 2 mentions for Can-Fite BioPharma. Addex Therapeutics' average media sentiment score of 0.93 beat Can-Fite BioPharma's score of -0.26 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Can-Fite BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Addex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Can-Fite BioPharma beats Addex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Liminatus Pharma?

Can-Fite BioPharma (NYSE:CANF) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Can-Fite BioPharma has higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K4.62-$7.63M-$35.80N/A
Liminatus PharmaN/AN/A-$10.21M-$0.44N/A

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Liminatus Pharma N/A N/A -299.79%

21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Can-Fite BioPharma and Can-Fite BioPharma both had 2 articles in the media. Liminatus Pharma's average media sentiment score of 0.38 beat Can-Fite BioPharma's score of -0.26 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Liminatus Pharma Neutral

Can-Fite BioPharma presently has a consensus target price of $42.50, suggesting a potential upside of 1,386.53%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Liminatus Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Liminatus Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Can-Fite BioPharma beats Liminatus Pharma on 8 of the 11 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Synlogic?

Can-Fite BioPharma (NYSE:CANF) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Can-Fite BioPharma has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K4.62-$7.63M-$35.80N/A
Synlogic$8K1,155.08-$23.36M-$0.06N/A

Can-Fite BioPharma's return on equity of 0.00% beat Synlogic's return on equity.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
Synlogic N/A -26.47%-18.00%

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Can-Fite BioPharma had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for Synlogic. Synlogic's average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.26 indicating that Synlogic is being referred to more favorably in the news media.

Company Overall Sentiment
Can-Fite BioPharma Neutral
Synlogic Neutral

Can-Fite BioPharma currently has a consensus price target of $42.50, indicating a potential upside of 1,386.53%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Synlogic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Synlogic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Can-Fite BioPharma has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

Can-Fite BioPharma beats Synlogic on 10 of the 15 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Genprex?

Genprex (NASDAQ:GNPX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

14.1% of Genprex shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.3% of Genprex shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Can-Fite BioPharma has a consensus price target of $42.50, indicating a potential upside of 1,386.53%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Can-Fite BioPharma's return on equity of 0.00% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
GenprexN/A -247.32% -176.73%
Can-Fite BioPharma N/A N/A N/A

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Genprex. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 1 mentions for Genprex. Genprex's average media sentiment score of 1.87 beat Can-Fite BioPharma's score of -0.26 indicating that Genprex is being referred to more favorably in the media.

Company Overall Sentiment
Genprex Very Positive
Can-Fite BioPharma Neutral

Can-Fite BioPharma has higher revenue and earnings than Genprex. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$16.23M-$14.14N/A
Can-Fite BioPharma$405K4.62-$7.63M-$35.80N/A

Genprex has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Can-Fite BioPharma beats Genprex on 11 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity.

Company Net Margins Return on Equity Return on Assets
ObsEvaN/A -416.36% -92.01%
Can-Fite BioPharma N/A N/A N/A

In the previous week, Can-Fite BioPharma had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Can-Fite BioPharma and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat Can-Fite BioPharma's score of -0.26 indicating that ObsEva is being referred to more favorably in the media.

Company Overall Sentiment
ObsEva Neutral
Can-Fite BioPharma Neutral

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

Can-Fite BioPharma has higher revenue and earnings than ObsEva. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEvaN/AN/A-$58.38M-$0.92N/A
Can-Fite BioPharma$405K4.62-$7.63M-$35.80N/A

Can-Fite BioPharma has a consensus target price of $42.50, indicating a potential upside of 1,386.53%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Can-Fite BioPharma beats ObsEva on 10 of the 14 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CANF vs. The Competition

Export
MetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$1.87M$974.88M$6.43B$22.84B
Dividend YieldN/A4.84%2.67%4.11%
P/E Ratio-1.601.4824.4830.18
Price / Sales4.62130.43501.1820.99
Price / CashN/A20.0642.3623.85
Price / Book1.627.9310.434.59
Net Income-$7.63M-$4.69M$3.56B$1.07B
7 Day Performance-9.53%-1.39%-1.30%-0.59%
1 Month Performance-18.55%3.58%0.99%-1.13%
1 Year Performance-87.12%96.67%19.51%18.95%

Can-Fite BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CANF
Can-Fite BioPharma
2.0672 of 5 stars		$2.86
-1.8%		$42.50
+1,386.5%		-86.9%$1.87M$405KN/A8
ADXN
Addex Therapeutics
0.7169 of 5 stars		$6.43
-3.4%		N/A-31.3%$8.19M$210KN/A30
LIMN
Liminatus Pharma
0.4773 of 5 stars		$0.20
+8.3%		N/AN/A$8.08MN/AN/AN/A
SYBX
Synlogic
N/A$0.70
+1.4%		N/A-42.3%$8.07M$8KN/A80
GNPX
Genprex
1.1663 of 5 stars		$0.74
-2.0%		N/A-95.7%$7.94MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel